Aimco Pesticides Limited Overview
Aimco Pesticides is a promoter-controlled Indian micro-cap agrochemical manufacturer that operates a single multi-product plant at Lote Parshuram (Ratnagiri, Maharashtra) with installed capacity of 18,500 MT per annum. Historically an export-led technical-grade producer — it was among the earliest Indian commercializers of chlorpyrifos and triclopyr technical and added bifenthrin in 2017 — the company also sells bulk (B2B) formulations and a growing portfolio of domestic branded formulations through its own distributor network. Roughly half of revenue has come from exports to Australia, the USA, Malaysia, Brazil, Africa and the Gulf. Since FY2022's record year (revenue INR 312 Cr), the business has contracted sharply under Chinese price competition, global channel destocking and the expiry of a large contract-manufacturing agreement; it has posted four consecutive annual losses and net worth has fallen to INR 17.7 Cr. Management is pivoting to branded formulations, new molecules and overseas subsidiaries while its credit standing deteriorates.
What the company does
Aimco Pesticides manufactures, markets and exports crop-protection chemicals across the three principal classes — insecticides, fungicides and herbicides — and to a lesser extent rodenticides and fumigants. It describes itself in exchange filings as a diversified, integrated agrochemical company engaged in manufacturing and trading of agrochemical products, including technical grade pesticides, formulations and a wide range of agrochemical inputs (Annual Report FY2024-25, as summarized by Screener). Its portfolio spans approximately 11 technical-grade active ingredients, 90+ formulations and 300+ branded SKUs (CARE Ratings, Jul 2023).
Business model and revenue streams
| Revenue stream | Description | Customer type | Margin profile (per management/CARE) |
|---|---|---|---|
| Technicals (manufactured active ingredients) | Technical-grade chlorpyrifos (ethyl and methyl), triclopyr, bifenthrin and other molecules, sold in bulk to formulators in India and abroad; also produced under contract manufacturing | Global and Indian agrochemical companies, overseas registrants/distributors (primarily Australia, USA) | Described by CARE as low-margin relative to branded formulations; management has also called technical sales higher-margin than B2B formulations |
| B2B formulations | Bulk formulated products supplied to other companies for re-branding | Indian and overseas agrochemical marketers | Lowest margin; consciously de-emphasized from FY2021 |
| Branded formulations (B2C) | Company-branded formulations sold to farmers through distributors and dealers in India | Distributors / retailers / farmers | Highest margin; strategic growth focus since FY2024 |
| Trading | Traded agrochemical products | Mixed | Secondary |
The company has consistently presented four revenue streams in its investor presentations (Q1FY21, Q3FY21, Q4FY23, Q4FY25 presentations):
The revenue model is entirely product-based (no service, subscription or licensing income of significance). Contract manufacturing — notably a three-year agreement from 1 April 2021 with an unnamed Indian agrochemical major, expected to generate INR 225–250 Cr over its tenure (company press release, March 2021, via AgroPages) — is a product-supply arrangement rather than a fee-for-service model.
Value-chain position
Aimco sits in the middle of the agrochemical value chain: it buys intermediates and raw materials (around half imported, predominantly from China, per CARE Oct-2025), synthesizes active ingredients (technicals), and either sells technicals downstream or formulates them into end-use products. In the domestic branded channel it reaches the farm gate via distributors. It does not undertake proprietary new-active-ingredient discovery at scale; its R&D focus is process chemistry for off-patent (generic) molecules.
Customer types and end-markets
Export customers: formulators and registrants in Australia, USA, Malaysia, Brazil, Africa and Gulf markets; historically ~42–45 export countries (Q3FY21 presentation; CARE Jul-2023). Exports were ~50% of revenue in FY2023 (CARE, Sep 2023).
Domestic B2B customers: Indian agrochemical companies (including the contract-manufacturing counterparty, FY2022–FY2024).
Domestic farmers via distributors: branded formulations sold primarily in West Bengal, Gujarat, Odisha, Andhra Pradesh, Tamil Nadu, Madhya Pradesh and Maharashtra (Q4FY25 earnings presentation). An earlier broker profile cites 285 active distributors (domestic and overseas) — date of that figure not confirmed.
Customer concentration: top ten customers contributed more than 50% of revenue in FY2024 (CARE, Oct 2025).
Independent characterization
Aimco is best understood as a sub-scale, generic-molecule technical producer that tried to migrate up the value chain into domestic brands just as the global generic agrochemical cycle turned down. Its legacy strengths (early-mover process know-how in chlorpyrifos/triclopyr, export registrations, a flexible plant) became liabilities as chlorpyrifos faced regulatory restrictions in major markets and Chinese producers flooded generic markets after 2022. The company's economics are highly exposed to (i) export price realization for a handful of molecules, (ii) Chinese raw-material costs, and (iii) Indian monsoon-driven seasonality in the branded business. With FY2026 revenue of INR 153.9 Cr and negative EBITDA, it lacks the scale to absorb fixed costs, and its balance sheet is now sustained largely by supplier credit (payables of INR 87.3 Cr against equity of INR 17.7 Cr at 31 Mar 2026).
Strategy
Stated strategy themes (paraphrased from filings, calls and CARE summaries)
-
Mix shift to branded formulations. From FY2024, management planned to focus on branded formulations because technicals are lower-margin relative to brands (CARE, Jun 2024 / Oct 2025). Branded share rose from 22% (FY2022) to 29% (FY2023); brand growth was reported in FY2025.
-
New molecules less exposed to China. Three new molecules entered production in FY2025, chosen because Chinese players do not supply them at scale; two had been stabilized by mid-2025 with own-brand formulations launched for both (9 Jun 2025 call; CARE).
-
De-risking raw-material supply. Management aims to reduce reliance on Chinese intermediates in favour of local sources (CARE).
-
Portfolio adjacencies. Planned entry into plant growth regulators, bio-nutrients and bio-stimulants (Annual Report FY2025 summary).
-
International subsidiaries. Build-out of Aimco KREPL Australia (2024–25) and recapitalization of Aimco International FZE (Dubai) and Aimco Ecoscience (India).
-
Research partnerships. University of Melbourne student research project on novel agricultural products (Jun 2026).
-
Liquidity management. Working-capital release in FY2026, debt repayment (INR 5.4 Cr net), and sale of a non-core residential asset.
Initiative register — last 24 months
| Date | Initiative | Type | Quantification | Status |
|---|---|---|---|---|
| May 2024 – Jun 2025 | Aimco KREPL Australia set up and capitalized | Market expansion | AUD 10,000 + AUD 30,000 | Subsidiary active; revenue not disclosed |
| Dec 2024 | Additional capital to Aimco International FZE | Market expansion | AED 150,000 | Completed |
| Dec 2024 – Jan 2025 | Additional capital to Aimco Ecoscience Ltd | Adjacency (inferred bio/eco) | INR 5 lakh | Completed |
| Jan–Mar 2025 | Preferential issue | Capital raising | 2,00,000 shares; INR 2.02 Cr | Allotted 6 Mar 2025 |
| FY2025 | Three new molecules commercialized | Product | Not quantified | Two stabilized by Jun 2025 |
| Jun 2025 | FY2026 revenue target | Guidance | INR 225 Cr | Missed (actual INR 153.9 Cr) |
| May–Sep 2026 | Sale of Juhu flat to promoter director | Asset monetization | INR 4.776 Cr | Approved at AGM 25 Sep 2026; completion not confirmed |
| Jun 2026 | University of Melbourne research agreement (via Aimco International FZE) | R&D | AUD 191,096.40 incl. GST | Signed 19 Jun 2026 |
| 2025–2026 | Plant growth regulators / bio-stimulants entry | Product adjacency | Not quantified | No launches disclosed |
Sustainability/ESG commitments: none quantified. Cost programs with targets: none publicly announced.
Medium-term financial targets / guidance
The only quantified guidance located is the FY2026 revenue target of INR 225 Cr (June 2025), which was missed by 32%. No FY2027 guidance, margin targets or medium-term plan has been disclosed in sources reviewed. Investor conference calls appear to have lapsed after June 2025 (Screener lists no calls after Jun 2025).
Products & Services
Technical-grade active ingredients (manufactured)
| Product | Class | Description / capability | Target customer | Launch year | Pricing model | Source |
|---|---|---|---|---|---|---|
| Chlorpyrifos technical (ethyl and methyl) | Organophosphate insecticide | Flagship legacy molecule; company claims early-mover status in India after Dow | Export formulators (Australia, USA, others) and domestic formulators | Not disclosed (pre-2001) | Bulk, spot/contract pricing; not disclosed | Investor presentations FY21; MarketScreener profile |
| Triclopyr technical | Pyridine-class herbicide (woody/broadleaf weed control) | Second flagship; supplied to export markets | Export registrants (notably Australia/USA) | 2,001 | — | Q3FY21 presentation |
| Bifenthrin technical | Pyrethroid insecticide | Added to diversify technical portfolio | Export and domestic | 2,017 | — | Q3FY21 presentation |
| Imidacloprid | Neonicotinoid insecticide | Production started and launched in India in FY2002-03; current status not confirmed | Domestic | FY2003 | — | IIFL summary |
| DDVP (dichlorvos) | Organophosphate insecticide/fumigant | Plant can switch to DDVP with minor modifications; branded "AIMCO-DDVP" referenced in FY23 presentation | Domestic | — | — | IIFL; Q4FY23 presentation |
| Glyphosate | Herbicide | Plant flexibility cited; current production not confirmed | — | — | — | IIFL |
| Three new molecules (FY2025) | — | Started in FY2025; two stabilized with production efficiencies by Jun 2025; selected because Chinese players do not supply them at scale | Export and own-brand formulations | FY2025 | — | CARE (Jun 2024, Oct 2025); Q4 FY25 call |
| Other technicals (to total ~11) | Insecticides, fungicides, herbicides | Company reports "about a dozen" / 11 technicals | — | Various | — | Q4FY25 presentation; CARE Jul 2023 |
| Hydroquinone (historical) | Non-agro photographic chemical | 130 tpa plant | Industrial | Historical | — | IIFL summary |
Installed capacity across the plant: 18,500 MT per annum (CARE, Oct 2025 / Jun 2026). Molecule-wise capacity and utilization are not publicly disclosed.
Formulations
| Category | Scope | Source |
|---|---|---|
| Formulations manufactured | 90+ formulations: insecticides, fungicides, herbicides, combinations, rodenticides and fumigants | CARE Jul 2023; MarketScreener |
| Branded SKUs | 300+ branded SKUs | CARE Jul 2023 |
| B2B (bulk) formulations | Supplied to other companies in India and exported (formulation export business) | Aug 2020 conference call |
Named branded formulations (domestic)
| Brand | Disclosed in | Notes |
|---|---|---|
| Aimco ASTRA | Stockopedia profile (S&P data) | — |
| AIMFIRE | Stockopedia profile | — |
| AIMCOSTAR FS | Stockopedia profile | "FS" denotes a flowable seed-treatment formulation type |
| Aimco TEJA | Stockopedia profile | — |
| Aimco ALTROZ | Stockopedia profile | — |
| Aimco WEED NASHAK | Stockopedia profile | Herbicide (name means "weed destroyer") |
| AIMCO BARRIER | Stockopedia profile | — |
| Aimco JUMPER | Stockopedia profile | — |
| AIMPYRAD | Stockopedia profile | — |
| AIMCO MIX | Stockopedia profile | — |
| Aimco Ace | Stockopedia profile | — |
| BYKILL | Stockopedia profile | — |
| ANACONDA | Q4FY25 earnings presentation | — |
| PYRIBAN | Q4FY25 earnings presentation | — |
| AIMCO-DDVP | Q4FY23 earnings presentation | Dichlorvos-based |
Active ingredients, launch years and pricing for individual brands are not disclosed in sources reviewed; the list below reproduces brand names as published.
Stockopedia's profile cites a portfolio of "approximately 11 molecules" behind the branded range.
Pipeline / adjacent categories
The company has stated an intention to launch Plant Growth Regulators (PGR), bio-nutrients and bio-stimulants (Annual Report FY2025 and CARE, as summarized by Screener). In June 2026 it funded a student research project at the University of Melbourne on "novel products for agriculture" (AUD 191,096.40 including GST, via Aimco International FZE). No launch dates or revenue targets for these categories are disclosed.
Services
No service, licensing or subscription offerings are disclosed. Contract manufacturing (toll/custom supply of an existing technical) was undertaken FY2022–FY2024.
Financial Narrative
All tables: consolidated, INR Cr unless stated; source S&P Global Market Intelligence via StockAnalysis.com (updated 12 Aug 2026), cross-checked with Screener.in (C-MOTS) and CARE Ratings. FY2026 figures are audited (board approval 28 May 2026).
Income statement
Notes: (a) Screener reports FY2025 EPS of INR -7.40 versus S&P's INR -7.55, reflecting weighted-share differences after the March 2025 allotment. (b) S&P revised FY2026 gross profit from INR 32.1 Cr (earlier snapshot) to INR 30.3 Cr after reclassification; latest used. (c) CARE's standalone FY2026 PBILDT is INR -10.33 Cr versus consolidated EBITDA of INR -7.7 Cr here — the gap reflects FX losses (INR 4.6 Cr) being classified differently.
Margins and growth
Revenue CAGR: FY2022→FY2026 (4 years) = -16.2%; FY2021 (INR 176 Cr, Screener)→FY2026 (5 years) = -2.6% (Screener reports 5-year sales CAGR of -2% / -2.48%).
Quarterly trajectory (most recent five quarters)
Source: Screener.in consolidated quarterly results. Discrepancies: Q1FY27 sales are INR 21.97 Cr per Screener but INR 21.79 Cr per Capital Market/Business Standard (13 Aug 2026), which reports a 54.59% YoY decline; a ScanX summary cites Q1FY27 net profit of INR 65.94 lakh (likely standalone) versus consolidated INR 0.61 Cr. Standalone Q2FY26 and Q3FY26 losses were reported as INR 3.56 Cr and INR 2.51 Cr respectively; standalone Q4FY26 loss was INR 3.96 Cr on standalone revenue of INR 30.24 Cr.
Balance sheet
Notes: Retained earnings turned negative (INR -7.6 Cr) at 31 Mar 2026. Zerodha/Tijori reports net debt of INR 12.68 Cr at Mar-2026, consistent with the above. CARE reports overall gearing of 0.58x / 0.70x / 0.89x for FY2024–FY2026.
Ratio analysis
Net debt / EBITDA: FY2022 net cash; FY2023 3.6x; FY2024–FY2026 not meaningful (negative EBITDA). ROE, ROA, ROIC, current ratio, D/E, coverage and turnover are analyst calculations from the S&P data above.
Commentary on trends, inflections and drivers
Revenue. FY2022's 75.6% growth to a record INR 312 Cr coincided with the first year of the three-year contract-manufacturing agreement signed in March 2021 (expected INR 225–250 Cr over three years, i.e., roughly INR 75–85 Cr per year) and with a strong global generic-agrochemical pricing cycle. The 33.9% collapse in FY2023 reflects the global destocking and Chinese price war that CARE explicitly cited (lower stock liquidation, inventory build-up, higher sales returns and weak export demand — CARE, Jul 2023). FY2024 was flat; the contract term ended in March 2024 (analyst inference from the original tenure — renewal not disclosed). FY2025 fell 4.4% despite management's claim of branded growth, and FY2026's 22.2% decline — against a management target of INR 225 Cr (9 Jun 2025 call) — was a 32% miss. The decline accelerated through FY2026: quarterly sales fell from INR 48.3 Cr (Q1) to INR 30.6 Cr (Q4) and INR 22.0 Cr in Q1FY27, a 55% YoY drop.
Gross margin. Gross margin has been volatile within a 16–22% band, troughing at 15.9% in FY2024 when high-cost inventory was liquidated into falling prices, and recovering to 22.0% in FY2025 as the branded mix improved. The FY2026 dip to 19.6% and the Q1FY27 rebound (TTM gross margin 25.3%; Q1FY27 OPM 8.2%) suggest the company is deliberately shrinking low-margin technical/B2B volumes — consistent with higher margin on far lower revenue.
Operating leverage. Fixed costs (SG&A + other opex ≈ INR 38 Cr in FY2026) now exceed gross profit (INR 30.3 Cr), so EBITDA is structurally negative at current scale. A rough breakeven at a 20% gross margin requires revenue of ~INR 190 Cr; at 25%, ~INR 150 Cr (analyst estimate, assuming fixed costs hold flat).
Below-the-line. FX losses rose to INR 4.6 Cr in FY2026 (from INR 1.2 Cr), a significant item for a company of this size, likely reflecting import payables in foreign currency. Interest expense fell in FY2026 as debt was repaid. Tax credits (INR 3.6 Cr) cushioned losses, but the corresponding deferred-tax asset has grown to INR 9.6 Cr — 54% of equity — whose recoverability depends on a return to taxable profits.
Balance sheet and liquidity. Equity has shrunk by 65% in four years (INR 50.5 Cr → INR 17.7 Cr). The company moved from net cash (FY2022) to persistent net debt of INR 12–16 Cr. Working capital turned sharply negative (INR -20.2 Cr) because payables (259 days) far exceed receivables and inventory days — CARE notes the low operating cycle results from late payments to creditors, with suppliers granting 90–120 days' clean credit. FY2026 operating cash flow (INR 5.7 Cr) was generated almost entirely by working-capital release (receivables down INR 23 Cr, inventory down INR 19 Cr, partly offset by payables paydown of INR 27 Cr), not by earnings. Cash fell to INR 2.6 Cr. Bank lines are heavily utilized (cash credit ~96%, EPC/PCFC ~72% over the 12 months to Aug 2024 — CARE). The attempt to sell a Mumbai flat for INR 4.78 Cr to "support immediate working capital and cash flow requirements" (postal-ballot notice, Jun 2026) underscores liquidity strain.
Capital allocation. Capex has been cut to maintenance levels (INR 1.2–1.9 Cr in FY2025–FY2026 versus INR 6.7–7.8 Cr in FY2022–FY2023). Dividends were suspended after FY2023. The only equity raise was INR 2.02 Cr (March 2025).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Relationship | Jurisdiction | Role (as disclosed) | Source |
|---|---|---|---|---|
Aimco Pesticides Ltd | Parent / listed entity | India | Manufacturing, domestic and export sales | Filings |
Aimco International FZE | Wholly owned subsidiary | UAE (Dubai) | International sales/trading office; counterparty to University of Melbourne research agreement (Jun 2026) | BSE (Dec 2024, Jun 2026) |
Aimco KREPL Australia Pty Ltd | Wholly owned subsidiary (incorporated 7 May 2024; capitalized AUD 10,000 Dec 2024 + AUD 30,000 Jun 2025) | Australia | Market access / registration vehicle for Australia (inferred from purpose of investment; detailed business not disclosed) | BSE (Dec 2024, Jun 2025) |
Aimco Ecoscience Ltd | Wholly owned subsidiary | India | Not disclosed in detail (name suggests bio/eco-products; further INR 5 lakh invested Dec 2024/Jan 2025) | BSE |
Aimco KR Agro Pvt Ltd | — | India | — | ICICI Direct profile |
AIMCO KR Agro LLP | — | India | — | ICICI Direct profile |
“—” = not publicly disclosed.
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue = revenue from operations (INR Cr) | 207.2 | 197.7 | 153.9 |
YoY growth (%) | 0.4 | -4.6 | -22.2 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Operating income / EBIT (INR Cr) | -11.4 | -6.1 | -11.0 |
Pre-tax income (INR Cr) | -13.3 | -9.6 | -15.8 |
EBIT margin (%) | -5.5 | -3.1 | -7.1 |
Pre-tax margin (%) | -6.4 | -4.8 | -10.2 |
Business line share of revenue (%)
| Business line share of revenue (%) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Technical grade chemicals | — | 59 | 51 |
Branded formulations (domestic B2C) | 22 | 29 | — |
B2B formulations | — | 9 | — |
Domestic formulations (branded + B2B) share of total income | — | — | 49 |
Export share of revenue | — | 50 | — |
Implied revenue (INR Cr)
| Implied revenue (INR Cr) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Technical grade chemicals | — | 121.7 | 105.7 |
Branded formulations | 68.6 | 59.8 | — |
B2B formulations | — | 18.6 | — |
Income Statement and Per-Share Data
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 312.0 | 206.2 | 207.2 | 197.7 | 153.9 |
Other operating revenue | 0.7 | 0.5 | 0.2 | 0.6 | 0.3 |
Cost of revenue | 248.2 | 161.4 | 174.4 | 154.6 | 123.9 |
Gross profit | 64.5 | 45.3 | 33.0 | 43.6 | 30.3 |
SG&A | 10.7 | 15.0 | 18.7 | 18.8 | 16.7 |
Other operating expenses | 34.9 | 27.0 | 21.5 | 26.8 | 21.2 |
EBITDA | 18.3 | 3.3 | -7.3 | -2.1 | -7.7 |
Depreciation & amortization | 2.2 | 3.6 | 4.1 | 3.9 | 3.3 |
Operating income (EBIT) | 16.2 | -0.2 | -11.4 | -6.1 | -11.0 |
Interest expense | 1.5 | 2.4 | 2.6 | 3.0 | 1.4 |
FX gain/(loss) | -0.3 | -0.8 | -0.4 | -1.2 | -4.6 |
Pre-tax income | 14.5 | -2.8 | -13.3 | -9.6 | -15.8 |
Income tax (negative = credit) | 3.9 | -0.6 | -3.3 | -2.3 | -3.6 |
Net income | 10.7 | -2.2 | -10.0 | -7.2 | -12.2 |
EPS basic (INR) | 11.12 | -2.28 | -10.48 | -7.55 | -12.47 |
EPS diluted (INR) | 11.12 | -2.28 | -10.48 | -7.55 | -12.47 |
Dividend per share (INR) | 2.0 | 1.0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth (total revenue) | 75.6 | -33.9 | 0.4 | -4.4 | -22.2 |
Gross margin | 20.6 | 21.9 | 15.9 | 22.0 | 19.6 |
EBITDA margin | 5.9 | 1.6 | -3.5 | -1.1 | -5.0 |
Operating (EBIT) margin | 5.2 | -0.1 | -5.5 | -3.1 | -7.1 |
Net margin | 3.4 | -1.1 | -4.8 | -3.7 | -7.9 |
Effective tax rate | 26.6 | 21.9 | 24.6 | 24.5 | 22.7 |
Income Statement and Margin Analysis (%)
| Metric (INR Cr) | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Sales | 48.32 | 45.60 | 30.38 | 30.64 | 21.97 |
Operating profit | -1.15 | -3.42 | -2.15 | -4.41 | 1.79 |
OPM (%) | -2.38 | -7.50 | -7.08 | -14.39 | 8.15 |
Interest | 0.51 | 0.49 | 0.43 | 0.38 | 0.27 |
Depreciation | 0.81 | 0.89 | 0.86 | 0.85 | 0.85 |
Profit before tax | -2.37 | -4.77 | -3.30 | -5.35 | 0.87 |
Net profit | -1.50 | -4.02 | -2.53 | -4.16 | 0.61 |
EPS (INR) | -1.53 | -4.11 | -2.59 | -4.25 | 0.62 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric (INR Cr, at 31 March) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 167.0 | 145.6 | 149.6 | 176.0 | 129.6 |
Cash & short-term investments | 8.1 | 1.7 | 3.7 | 5.5 | 2.6 |
Trade & other receivables | 41.2 | 26.3 | 51.1 | 54.8 | 30.0 |
Inventory | 77.8 | 77.6 | 52.3 | 72.9 | 54.1 |
Total current assets | 136.9 | 111.0 | 109.4 | 136.7 | 89.1 |
Property, plant & equipment | 22.9 | 26.3 | 26.2 | 26.1 | 23.4 |
Goodwill & intangibles | 6.4 | 5.8 | 5.3 | 4.8 | 5.2 |
Deferred tax assets | 0 | 0.3 | 3.7 | 6.0 | 9.6 |
Trade payables | 109.0 | 76.2 | 83.7 | 114.9 | 87.3 |
Short-term debt incl. current portion of LTD | 0 | 12.6 | 16.6 | 19.5 | 14.5 |
Long-term debt | 0.01 | 0.01 | 1.8 | 0.2 | 0.05 |
Total debt incl. leases | 0.1 | 13.7 | 19.4 | 20.4 | 15.0 |
Net debt (negative = net cash) | -8.0 | 12.0 | 15.7 | 14.9 | 12.4 |
Total current liabilities | 114.2 | 96.3 | 109.5 | 142.6 | 109.3 |
Shareholders' equity | 50.5 | 46.3 | 35.0 | 29.9 | 17.7 |
Working capital (current assets – current liabilities) | 22.8 | 14.7 | -0.1 | -5.9 | -20.2 |
Book value per share (INR) | 52.69 | 48.30 | 36.55 | 30.55 | 18.06 |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 22.6 | -10.1 | 7.4 | 2.7 | 5.7 |
of which change in working capital | 7.1 | -11.5 | 14.0 | 3.4 | 16.7 |
Capital expenditure | -7.8 | -6.7 | -5.4 | -1.2 | -1.9 |
Free cash flow | 14.8 | -16.8 | 2.0 | 1.5 | 3.8 |
Dividends paid | -0.9 | -2.1 | -1.0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Equity issued | 0 | 0 | 0 | 2.0 | 0 |
Net debt issued/(repaid) | -11.0 | 12.4 | 5.1 | 1.0 | -5.4 |
Cash interest paid | 1.5 | 0.9 | 2.6 | 3.1 | 1.9 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, on average equity) | 23.4 | -4.5 | -24.7 | -22.3 | -51.3 |
ROA (%, on average assets) | 7.1 | -1.4 | -6.8 | -4.4 | -8.0 |
ROCE (%, Screener) | 31 | -1 | -18 | -12 | -34 |
Pre-tax ROIC (%, EBIT / year-end invested capital) | 38.1 | -0.3 | -22.5 | -13.6 | -36.5 |
Current ratio (x) | 1.20 | 1.15 | 1.00 | 0.96 | 0.82 |
Debt / equity (x) | 0.00 | 0.30 | 0.55 | 0.68 | 0.85 |
Interest coverage (EBIT / interest, x) | 11.0 | -0.1 | -4.3 | -2.0 | -7.7 |
Asset turnover (x, revenue / average assets) | 2.08 | 1.32 | 1.40 | 1.21 | 1.01 |
Debtor days (Screener) | 48 | 43 | 82 | 93 | 63 |
Inventory days (Screener) | 115 | 177 | 110 | 174 | 161 |
Payable days (Screener) | 161 | 174 | 177 | 274 | 259 |
Cash conversion cycle (days, Screener) | 2 | 47 | 15 | -8 | -35 |
Revenue by Region (%)
| Geographic metric | FY2021 | FY2023 | FY2024 |
|---|---|---|---|
Export share of revenue (%) | — | 50 | — |
Domestic formulations share of total income (%) | — | — | 49 |
Number of export countries (approx.) | 42 | 45 | — |
Business Lines
| Business line | Primary geographies | Evidence |
|---|---|---|
Technicals | Exports — primarily Australia and USA; also Malaysia, Brazil, Africa, Gulf | Investor presentations FY21–FY23; CARE Sep 2023 |
B2B formulations | Export formulation business and domestic bulk | Aug 2020 call |
Branded formulations | India — West Bengal, Gujarat, Odisha, Andhra Pradesh, Tamil Nadu, Madhya Pradesh, Maharashtra | Q4FY25 presentation |
Share Price & Returns
| Horizon | Return | Source |
|---|---|---|
1-year | -41% to -45% (various dates Sep–Oct 2026) | ScanX; Screener |
3-year | -29% CAGR (≈ -64% cumulative) | Screener |
5-year | -16% CAGR; ≈ -59% cumulative | Screener; ScanX |
10-year | -3% CAGR | Screener |
Share Count (million) and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shares outstanding (million) | 9.58 | 9.58 | 9.58 | 9.78 | 9.78 |
Book value per share (INR) | 52.69 | 48.30 | 36.55 | 30.55 | 18.06 |
EPS (INR) | 11.12 | -2.28 | -10.48 | -7.55 | -12.47 |
Dividend per share (INR) | 2.0 | 1.0 | 0 | 0 | 0 |
Free cash flow per share (INR) | 15.43 | -17.49 | 2.11 | 1.56 | 3.85 |
Valuation Multiples
| Multiple | Aimco | Comment |
|---|---|---|
Market cap (INR Cr) | 41.1 | 9.78 million shares |
Enterprise value (INR Cr) | 53.5 | Market cap + total debt INR 15.0 Cr – cash INR 2.6 Cr (31 Mar 2026) |
EV/Sales (FY2026) | 0.35x | Revenue INR 153.9 Cr |
EV/Sales (TTM) | 0.42x | TTM revenue INR 128.6 Cr |
P/B | 2.33x | BVPS INR 18.06 |
P/Tangible book | 3.29x | TBVPS INR 12.77 |
Dividend History
| Fiscal year | Dividend per share (INR) | Payout ratio (%) | Source |
|---|---|---|---|
FY2018 | — | 19 | Screener |
FY2019 | — | 19 | Screener |
FY2020 | — | 22 | Screener |
FY2021 | — | 46 | Screener |
FY2022 | 2.0 | 18 | S&P; Screener |
FY2023 | 1.0 (ex-date 18 Sep 2023, paid despite loss) | — | S&P; MarketsMOJO |
FY2024–FY2026 | 0 | 0 | S&P; Motilal Oswal (FY2026 nil) |
Agency by Date
| Date | Agency | Long-term | Short-term | Action | Source |
|---|---|---|---|---|---|
6 Oct 2022 | CARE | BBB-; Stable | A3 | Assigned/reaffirmed | CARE rating history |
20 Jul 2023 | CARE | BB+; Stable | A4+ | Downgrade | CARE |
29 Sep 2023 | CARE | BB+; Stable | A4+ | Reaffirmed | CARE |
6 Jun 2024 | CARE | BB; Stable | A4 | Downgrade | CARE |
3 Oct 2024 | CARE | BB; Stable | A4 | Reaffirmed | CARE |
6 Oct 2025 | CARE | BB-; Stable (INC) | A4 (INC) | Downgrade; Issuer Not Cooperating | CARE |
8 Jun 2026 | CARE | B-; Stable (INC) | A4 (INC) | Downgrade | CARE |
Debt Facilities
| Facility | Amount (INR Cr) | Maturity | Rating |
|---|---|---|---|
Fund-based / non-fund-based LT/ST | 16.00 | Revolving | B- / A4 (INC) |
Fund-based / non-fund-based LT/ST | 5.00 | Revolving | B- / A4 (INC) |
Forward contract (non-fund-based ST) | 1.00 | Revolving | A4 (INC) |
Term loan (long term) | 3.00 | 31 Mar 2027 | B- (INC) |
Total rated facilities | 25.00 | — | — |
Analyst Conclusions
Management guidance
No formal FY2027 guidance has been issued. The last quantified target (FY2026 revenue INR 225 Cr, June 2025) was missed by 32%. Management's strategic direction emphasizes branded formulations, new molecules, bio-inputs and the Australian subsidiary.
Consensus expectations
None — the stock has no analyst coverage.
Bull case
-
Margin inflection on a cleaned-up mix. Q1FY27 delivered an 8.2% operating margin and a net profit on revenue of only ~INR 22 Cr, and TTM gross margin reached 25.3%, suggesting that exiting low-margin technical/B2B volume has reset unit economics; restoring revenue to FY2025 levels (~INR 198 Cr) at a 25% gross margin would imply positive EBITDA of roughly INR 10 Cr.
-
Balance-sheet repair underway. Net debt fell from INR 15.7 Cr (FY2024) to INR 12.4 Cr (FY2026), FY2026 FCF was positive (INR 3.8 Cr), and the approved INR 4.78 Cr property sale could cut net debt by about a third.
-
Option value at a trough valuation. At ~0.4x EV/Sales and a market cap of ~INR 41 Cr, the market prices in continued decline; new molecules, branded growth and any rebound in generic export pricing (as industry destocking ends) offer asymmetric upside, with promoters holding 54.45% and no pledges.
Bear case
-
Revenue collapse is not just mix. Revenue fell 22% in FY2026 and ~55% YoY in Q1FY27 while peers such as Rallis (+9%) grew, indicating loss of competitiveness and working-capital-constrained selling rather than a deliberate pruning alone.
-
Solvency and liquidity risk. Equity of INR 17.7 Cr supports payables of INR 87.3 Cr and short-term debt of INR 14.5 Cr; current ratio is 0.82x and cash only INR 2.6 Cr. CARE's B- rating and non-cooperation could tighten bank and supplier credit, and a further year of losses at the FY2026 rate would nearly wipe out remaining equity.
-
Governance and disclosure discount. Rating-agency non-cooperation, discontinued investor calls, a related-party asset sale rejected by minorities then pushed through at the AGM, and family concentration across MD/CFO/board roles warrant a structural discount and raise the risk of value leakage.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q2 FY27 results | ~Mid-Nov 2026 | Whether Q1 profitability holds through the kharif-season quarter; revenue trajectory |
| Completion of Juhu flat sale | H2 FY2027 | Receipt of INR 4.78 Cr and use of proceeds |
| Term-loan maturity | 31 Mar 2027 | Repayment / refinancing of INR 3 Cr term loan |
| CARE rating actions | Ongoing | Further downgrade or withdrawal; any return to cooperation |
| Working-capital metrics | Quarterly | Payable days (259 at FY2026), bank-line utilization, cash |
| Rabi season (Oct 2026 – Mar 2027) | Q3–Q4 FY27 | Branded formulation sell-through |
| New molecules / bio-inputs | FY2027 | Disclosure of revenue contribution or launches |
| Australian subsidiary | FY2027 | First revenue disclosures or registrations |
| Export pricing for generics | Ongoing | Chinese pricing for chlorpyrifos/bifenthrin/triclopyr |
| Deferred-tax asset | FY2027 audit | Any impairment of INR 9.6 Cr DTA |
| Investor communication | Ongoing | Resumption of earnings calls/presentations |
Concluding analyst verdict
Aimco Pesticides is a distressed micro-cap whose investment case now rests on survival rather than growth. The company that delivered INR 312 Cr of revenue and INR 10.7 Cr of profit in FY2022 has since lost half its revenue, four consecutive years of earnings, and two-thirds of its equity. FY2026 was the low point on the annual numbers — revenue down 22% to INR 153.9 Cr, EBITDA of INR -7.7 Cr and a net loss of INR 12.2 Cr — and Q1FY27's return to a small profit came on revenue that more than halved. That combination suggests a business deliberately shrinking toward its higher-margin core, but also one that may be constrained by liquidity from selling more.
The balance sheet is the binding constraint. With INR 17.7 Cr of equity, INR 2.6 Cr of cash, a current ratio below 1x and suppliers effectively financing operations, Aimco has little room for another loss-making year. CARE's slide from BBB- to B- in under four years, compounded by the company's non-cooperation, is a material warning, as is the need to sell a residential flat to a promoter director to fund working capital.
There are genuine assets — a flexible 18,500 MTPA plant, decades of process know-how, export registrations, a branded franchise and new molecules — and the shares trade at roughly 0.4x EV/Sales. But the governance profile (family-concentrated management, related-party dealings, sparse disclosure) and the structural decline of the legacy chlorpyrifos franchise argue for caution.
Verdict: High-risk, speculative. The stock is investable only for special-situation investors willing to underwrite a turnaround on the evidence of sustained quarterly profitability, completion of the asset sale, stabilizing revenue above ~INR 40 Cr per quarter, and restored transparency with lenders and rating agencies. Until at least two of these are visible, the downside risks — equity erosion, credit tightening and minority value leakage — outweigh the option value embedded in the depressed valuation.
DATA NOTES & SOURCES
The FY2025-26 annual report and recent earnings-call/presentation PDFs on bseindia.com could not be retrieved directly; data from them is used only where quoted in search snippets or third-party summaries.
Primary sources consulted:
-
S&P Global Market Intelligence data via StockAnalysis.com — income statement, balance sheet, cash flow (BOM:524288), updated 12 Aug 2026
-
Screener.in — consolidated quarterly/annual results, ratios, shareholding, document index (accessed Oct 2026)
-
CARE Ratings press releases on Aimco Pesticides — 20 Jul 2023, 29 Sep 2023, 6 Jun 2024, 6 Oct 2025, 8 Jun 2026
-
BSE filings: Outcome of board meeting (23 Dec 2024); Q4FY25 earnings presentation (2 Jun 2025); Q4 FY25 earnings call transcript (9 Jun 2025); investor presentations Jul 2020, Sep 2020, Feb 2021, Jun 2021, May 2023; Aug 2020 call transcript
-
ScanX (Dhan) summaries of BSE disclosures: FY2026 results (29 May 2026), postal ballot notice (23 Jun 2026), scrutinizer report (25 Jul 2026), University of Melbourne agreement (19 Jun 2026), director appointment/death disclosures (Sep 2025), AGM outcome (25 Sep 2026)
-
Business Standard / Capital Market — Q1 FY27 results (13 Aug 2026)
-
Whalesbook — Q4 FY26 standalone/consolidated results (28 May 2026)
-
Investywise — 39th AGM schedule (12 Aug 2026)
-
AgroPages — contract-manufacturing agreement (Mar 2021)
-
SEBI open-offer documents (2005–2006)
-
Company website (aimcopesticides.com) management pages; MarketScreener, Stockopedia, Simply Wall St, Pocketful, Business Standard, MarketsMOJO, Bajaj Finserv, Trendlyne, ICICI Direct, IIFL, Aditya Birla Capital, Sharekhan, Fyers, Zerodha, Kotak Securities broker profiles
-
Peer data: Rallis India FY2026 press release (27 Apr 2026) and Arihant/Multibagg summaries; Dhanuka Agritech FY2026 press release (19 May 2026) and Multibagg/AskFuzz summaries; India Pesticides Q1 FY27 summary (AskFuzz)
-
Industry data: Rubix Data Sciences (Jun 2025); Mordor Intelligence; P&S Intelligence; Nexdigm
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure on board | Background / education | Age (disclosed, varies by source) | Source |
|---|---|---|---|---|---|
Mayoor (Mayur) Amin | Chairman, Independent Non-Executive Director | Chairman since 12 Feb 2025; earlier listed as non-independent/independent director | — | — | IndMoney; Pocketful; Stockopedia |
Dr. Samir Pradeep Dave | Managing Director (Executive, promoter) | Director since May 1995; MD since 13–14 Feb 2024; re-appointed MD at 39th AGM (25 Sep 2026) | PhD in synthetic organic chemistry (University of Bombay), trained under Dr. A. V. Rama Rao; 20+ years in pesticide process R&D; heads R&D and production; founder director of AgroCare (global generic agrochemical association, Belgium); director, Agriculture Skill Council of India | 54–59 | Company website; MarketScreener; Simply Wall St |
Pradeep Pushkarrai Dave | Founder; Executive Whole-Time Director (some sources list as non-executive) | Since incorporation (1987) | Chemistry graduate (University of Mumbai); 40+ years in pesticides; President of PMFAI (since 2010); governing body member, Institute of Pesticide Formulation Technology; Chemtech Foundation board; former Chairman, Society of Chemical Industry (India) | 78–83 | Company website; MarketScreener; CARE |
Ashit Pradeep Dave | Whole-Time Director & CFO | Since 19 Aug 1996 | Commerce graduate; MEP from IIM Ahmedabad; finance, legal and commercial lead | 50–54 | MarketScreener; company team page |
Tarlika Pradeep Dave | Non-Executive Director (promoter) | Since 15 Sep 2025 (5-year term to 14 Sep 2030) | ~30 years in pesticide industry; led Amisco Agro-Chem Ltd (principal promoter vehicle); wife of Pradeep Dave, mother of Samir and Ashit Dave | 80–81 | ScanX (BSE disclosure) |
Ashok Kundanmal Jain | Independent Non-Executive Director | — | — | — | Pocketful |
Jagat Harish Shah | Independent Non-Executive Director | — | — | — | Pocketful |
Jignesh Anantrai Nagodra | Independent Non-Executive Director | — | — | — | Pocketful |
Reema Manoj Vara | Company Secretary & Compliance Officer | — | — | — | Pocketful; BSE filings |
“—” = not publicly disclosed.
Directors' Remuneration
| Executive | Salary (INR Cr) | Bonus | Stock awards | Total (INR Cr) | Fiscal year | Source |
|---|---|---|---|---|---|---|
Dr. Samir Dave (MD) | 1.20 | 0 | 0 | 1.20 | FY2024 | S&P data via Simply Wall St |
Ashit Dave (WTD & CFO) | 1.20 | 0 | 0 | 1.20 | FY2024 | S&P data via Simply Wall St |
Independent Chairman (sitting fees) | — | — | — | 0.009 | FY2024 | Simply Wall St |
Major Shareholders
| Holder | Shares | Stake (%) | Category | Source / date |
|---|---|---|---|---|
Amisco Agro-Chem Ltd | 28,87,925 | 29.52 | Promoter group | Bajaj Finserv / MarketsMOJO (Mar–Jun 2026) |
Pradeep Pushkarrai Dave | 9,02,091 | 9.22 | Promoter | Bajaj Finserv |
Ashit Pradip Dave | 4,82,077 | 4.93 | Promoter | Bajaj Finserv |
Samir Pradeepbhai Dave | 4,04,018 | 4.13 | Promoter | Bajaj Finserv |
Damodar Prasad Agarwal | — | 3.57 | Public (largest non-promoter) | MarketsMOJO (Mar 2026) |
Priyal Dave | 1,50,500 | 1.54 | Promoter group | Bajaj Finserv |
Shail Samir Dave | 1,50,100 | 1.53 | Promoter group | Bajaj Finserv |
Shreya Ashit Dave | 92,787 | 0.95 | Promoter group | Bajaj Finserv |
Nandini Ashit Dave | 92,287 | 0.94 | Promoter group | Bajaj Finserv |
Diya Ashit Dave | 92,287 | 0.94 | Promoter group | Bajaj Finserv |
Meghna Samir Dave | 56,000 | 0.57 | Promoter group | Bajaj Finserv |
Late Elizabeth Shrivastava (estate) | 16,586 | 0.17 | Promoter group (ceasing per SEBI rules) | Bajaj Finserv |
“—” = not publicly disclosed.
Shareholding Pattern
| Category (%) | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|
Promoters | 54.45 | 54.45 | 54.45 | 54.45 | 54.45 |
FIIs | 0.04 | 0.04 | 0.00 | 0.00 | 0.00 |
DIIs | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
Public | 45.47 | 45.48 | 45.55 | 45.55 | 45.55 |
Number of shareholders | 11,398 | 11,354 | 7,987 | 7,902 | 7,792 |
Competitive Landscape
Competitors by Segment
| Business line | Named competitors | Nature of competition |
|---|---|---|
Export technicals (chlorpyrifos, triclopyr, bifenthrin, other generics) | Chinese generic producers (as a class, cited by CARE as the main pressure); Indian technical producers: UPL, Gharda Chemicals (unlisted), Meghmani Organics, Bharat Rasayan, India Pesticides, Heranba Industries, Punjab Chemicals & Crop Protection, Bhagiradha Chemicals & Industries, Shivalik Rasayan; originator Corteva (Dow legacy) in triclopyr/chlorpyrifos | Price-driven; scale and backward integration decisive |
Domestic branded formulations | Dhanuka Agritech, Rallis India (Tata), UPL (Advanta/domestic), PI Industries (domestic brands), Bayer CropScience India, Sumitomo Chemical India, Insecticides (India), Best Agrolife, GSP Crop Science, Dharmaj Crop Guard, NACL Industries, Crystal Crop Protection (unlisted) | Distribution reach, brand pull, credit terms to dealers |
Global generic formulation/registration players | Sharda Cropchem (registration-led exporter), Nova Agritech | Registration portfolios in export markets |
Small-cap peers (similar scale) | Super Crop Safe, Bhaskar Agrochem, Phyto Chem (India) | Similar sub-scale generics |
Peer Comparison FY2026
| Metric | Aimco Pesticides | Rallis India | Dhanuka Agritech | India Pesticides |
|---|---|---|---|---|
Revenue from operations (INR Cr) | 153.9 | 2,897 | 2,019.8 | — |
Revenue growth FY2026 (%) | -22.2 | 8.8 | -0.8 | Q1FY27 standalone -8.6 YoY |
EBITDA (INR Cr) | -7.7 | 362 | — | — |
EBITDA margin (%) | -5.0 | 12.5 | — | Q1FY27 OPM 14.1 |
Net profit (INR Cr) | -12.2 | 184 | 287.2 | Q1FY27 PAT 22.7 |
Net margin (%) | -7.9 | 6.4 | 14.2 | — |
Balance sheet | Net debt INR 12.4 Cr; equity INR 17.7 Cr | Cash & liquid INR 541 Cr | Buyback INR 70 Cr announced | Debt-free, net cash |
Peer Comparison FY2026 by Company
| Company | Market cap (INR Cr) | P/E (x) | Annual PAT (INR Cr) |
|---|---|---|---|
PI Industries | 36,261 | 31.1 | 1,321 |
Sumitomo Chemical India | 24,892 | 43.0 | 543 |
Bayer CropScience India | 17,777 | 24.3 | 689 |
Sharda Cropchem | 6,971 | 11.1 | 681 |
Rallis India | 4,082 | 19.1 | 184 |
Shivalik Rasayan | 494 | 36.1 | 18 |
Nova Agritech | 218 | 16.9 | 13 |
Aimco Pesticides | 46 | — | -12 |



